Pharsight

Drugs that contain Ibrutinib

1. Imbruvica patents expiration

IMBRUVICA's oppositions filed in EPO
IMBRUVICA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7514444 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8735403 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8957079 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8697711 PHARMACYCLICS LLC Inhibitors of bruton'S tyrosine kinase
Dec, 2026

(2 years from now)

US9181257 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8008309 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Nov, 2027

(3 years from now)

US10106548 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10125140 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9725455 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9296753 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476284 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8497277 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8703780 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8754091 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8952015 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(2 years from now)

US8563563 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Apr, 2027

(3 years from now)

US9181257

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8957079

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US7514444

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8476284

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8497277

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8754091

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8697711

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of bruton'S tyrosine kinase
Jun, 2027

(3 years from now)

US8703780

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8735403

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8952015

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(3 years from now)

US8563563

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
Oct, 2027

(3 years from now)

US8008309

(Pediatric)

 PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
May, 2028

(4 years from now)

US9125889 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801883 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10751342 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801881 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US10004746 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US8999999 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US8754090 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10016435 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10653696 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US10478439 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9814721 PHARMACYCLICS LLC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US11672803 PHARMACYCLICS LLC Use of inhibitors of Brutons tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801883

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9801881

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US10751342

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US8754090

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9125889

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10016435

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10004746

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10478439

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9814721

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US8999999

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10653696

(Pediatric)

 PHARMACYCLICS LLC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US9713617 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10752634 PHARMACYCLICS LLC Crystalline forms of a brutons tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10961251 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10294231 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US10294232 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(9 years from now)

US9540382 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Aug, 2033

(9 years from now)

US10752634

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a brutons tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10961251

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10294231

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10294232

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10125140

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US10106548

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9725455

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9713617

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(9 years from now)

US9540382

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Feb, 2034

(9 years from now)

US9296753

(Pediatric)

 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Apr, 2034

(10 years from now)

US9795604 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10695350 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10463668 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Oct, 2034

(10 years from now)

US10463668

(Pediatric)

 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US9795604

(Pediatric)

 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10695350

(Pediatric)

 PHARMACYCLICS LLC Methods of treating and preventing graft versus host disease
Apr, 2035

(11 years from now)

US10828259 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10213386 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10010507 PHARMACYCLICS LLC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US9655857 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10010507

(Pediatric)

 PHARMACYCLICS LLC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10213386

(Pediatric)

 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10828259

(Pediatric)

 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US9655857

(Pediatric)

 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029
ODE*(ODE*) Aug 02, 2024
New Patient Population(NPP) Aug 24, 2025
Pediatric Exclusivity(PED) Feb 24, 2026
M(M-236) Jan 25, 2022
New Dosing Schedule(D-176) Aug 24, 2021
New Chemical Entity Exclusivity(NCE) Nov 13, 2018

NCE-1 date: 24 February, 2025

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma with 17p deletion; For the treatment of patients with waldenstrom's mac...

Dosage: TABLET;ORAL; CAPSULE;ORAL; SUSPENSION;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents